DNA Gyrase and Topoisomerase IV Targeting

Fluoroquinolones owe their bactericidal activity to two bacterial enzymes: DNA gyrase, which introduces negative supercoils ahead of the replication fork, and topoisomerase IV, which separates (decatenates) daughter chromosomes after replication. Both are type II topoisomerases that cut and reseal double-stranded DNA, and both are absent in this exact form in human cells, making them selective antibacterial targets.

Definition

DNA gyrase and topoisomerase IV are essential bacterial type II topoisomerases that pass one DNA duplex through a transient double-strand break in another; fluoroquinolone targeting refers to drug binding that stabilizes these enzymes on cleaved DNA, blocking replication and killing the bacterium.

Scope

The entry describes the two type II topoisomerase targets of fluoroquinolones, how supercoiling and decatenation make them essential, how the drugs trap them on cleaved DNA, the basis of selectivity over human topoisomerases, and how target mutations confer resistance. It is reference-educational, not prescribing guidance.

Core questions

• What distinct cellular roles do DNA gyrase and topoisomerase IV play?
• Why is gyrase often the primary target in Gram-negative bacteria and topoisomerase IV in many Gram-positive bacteria?
• How does trapping a type II topoisomerase on cleaved DNA produce lethal damage?
• How do mutations in gyrA/gyrB and parC/parE produce target-based resistance?

Key concepts

• DNA gyrase (negative supercoiling)
• Topoisomerase IV (decatenation)
• Type II topoisomerase double-strand passage
• Quinolone-resistance-determining region (QRDR)
• Primary versus secondary target
• Selective toxicity over human topoisomerase II
• gyrA/gyrB and parC/parE mutations

Mechanisms

Type II topoisomerases relieve and manage DNA topology by making a transient double-strand break in one duplex, passing a second duplex through it, and resealing the break. DNA gyrase uniquely introduces negative supercoils needed for replication and transcription, while topoisomerase IV chiefly decatenates interlinked daughter chromosomes so cell division can complete (Drlica & Zhao, 1997). Fluoroquinolones bind the enzyme-DNA complex in its cleaved state, stabilizing it and converting the essential enzyme into a generator of double-strand breaks; this 'topoisomerase poisoning' is mechanistically parallel to how certain anticancer drugs poison human topoisomerases, though the bacterial enzymes differ enough to permit selectivity (Pommier et al., 2010). Which enzyme is the primary lethal target varies by organism and drug, helping to explain spectrum differences. Mutations clustered in the quinolone-resistance-determining regions of gyrA/gyrB and parC/parE reduce drug binding and are a leading cause of resistance (Ruiz, 2003; Hooper, 1999).

Clinical relevance

Because gyrase and topoisomerase IV are essential and structurally distinct from human topoisomerases, they provide the selective basis for fluoroquinolone antibacterial action, and target mutations explain much clinically observed resistance. This is mechanistic background for understanding the class and resistance; it is not treatment or prescribing advice.

Evidence & guidelines

The enzymology and dual-target model are set out in foundational reviews (Drlica & Zhao, 1997), the topoisomerase-poisoning framework in comparative reviews spanning antibacterial and anticancer agents (Pommier et al., 2010), and the resistance mechanisms in dedicated reviews (Ruiz, 2003; Hooper, 1999). These are mechanistic references, not clinical guidelines.

History

DNA gyrase was identified in the mid-1970s as the enzyme that supercoils DNA and was soon recognized as the target of nalidixic acid and its successors. Topoisomerase IV was characterized later and shown to be a second quinolone target, refining the single-target picture into the dual-target model that now frames fluoroquinolone pharmacology and resistance.

Key figures

• Karl Drlica
• Yves Pommier
• David C. Hooper
• Joaquim Ruiz

Seminal works

• drlica-zhao-1997
• pommier-2010

Frequently asked questions

What is the difference between DNA gyrase and topoisomerase IV?

Both are bacterial type II topoisomerases, but gyrase chiefly introduces negative supercoils to aid replication and transcription, whereas topoisomerase IV chiefly separates interlinked daughter chromosomes after replication. Fluoroquinolones can act on both.

Why don't fluoroquinolones equally poison human topoisomerases?

Human cells use related type II topoisomerases, but the bacterial enzymes differ enough in structure that fluoroquinolones bind them far more avidly, providing the selectivity that underlies their antibacterial action. This selectivity is relative, not absolute.